Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Clostridium difficile infection? 144 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 144 reports of Clostridium difficile infection have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.3% of all adverse event reports for OCRELIZUMAB.

144
Reports of Clostridium difficile infection with OCRELIZUMAB
0.3%
of all OCRELIZUMAB reports
2
Deaths
78
Hospitalizations

How Dangerous Is Clostridium difficile infection From OCRELIZUMAB?

Of the 144 reports, 2 (1.4%) resulted in death, 78 (54.2%) required hospitalization, and 4 (2.8%) were considered life-threatening.

Is Clostridium difficile infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 144 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Clostridium difficile infection?

ADALIMUMAB (1,502) INFLIXIMAB (1,419) VEDOLIZUMAB (1,130) LENALIDOMIDE (814) VANCOMYCIN (743) METRONIDAZOLE (619) PREDNISONE (618) METHOTREXATE (588) RITUXIMAB (532) CIPROFLOXACIN (508)

Which OCRELIZUMAB Alternatives Have Lower Clostridium difficile infection Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Clostridium difficile infection Reports All Drugs Causing Clostridium difficile infection OCRELIZUMAB Demographics